November 3, 2025 – San Diego, CA — Leads & Copy — Kura Oncology, Inc. (Nasdaq: KURA) has received a $30 million milestone payment from Kyowa Kirin after the first patient was dosed in the second KOMET-017 Phase 3 trial of ziftomenib.
Kura Oncology has now received a total of $105 million in milestone payments and expects to receive up to $315 million in additional, near-term milestones under the collaboration.
The KOMET-017 (NCT07007312) trials evaluate ziftomenib with chemotherapy regimens in patients newly diagnosed with NPM1-mutated (NPM1-m) or KMT2A-rearranged (KMT2A-r) acute myeloid leukemia (AML).
Kura Oncology is developing ziftomenib, a menin inhibitor that targets certain genetic drivers of acute myeloid leukemias. The company also pioneers advancements in menin inhibition for acute leukemias and solid tumors and in farnesyl transferase inhibition to address mechanisms of adaptive and innate resistance in the treatment of solid tumors.
Greg Mann
858-987-4046
gmann@kuraoncology.com
Source: Kura Oncology
